Navigation Links
Johannes N. van den Anker, MD, PhD, Prominent Neonatal and Pediatric Clinical Pharmacologist, Joins NDA Partners
Date:5/15/2019

NDA Partners Chairman Carl Peck, MD, announced today that Johannes N. van den Anker, MD, PhD, a prominent neonatal and pediatric clinical pharmacologist and expert in pediatric and neonatal clinical trials and therapies, has joined the firm as an Expert Consultant.

Dr. van den Anker is Vice Chair of Pediatrics for Experimental Therapeutics, the Evan and Cindy Jones Chair in Pediatric Clinical Pharmacology, and serves as Director of the Division of Clinical Pharmacology at Children’s National Medical Center (Washington, DC). He is Professor of Pediatrics, Pharmacology & Physiology, and Genomics and Precision Medicine at The George Washington University (Washington, DC). He is also the Eckenstein-Geigy Distinguished Professor of Pediatric Pharmacology and Department Chair of Pediatric Pharmacology and Pharmacometrics, University Children’s Hospital (Basel, Switzerland), and Adjunct Professor of Medicine, Pediatrics, Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine (Baltimore, MD), and Adjunct Faculty, Intensive Care and Department of Surgery, Erasmus MC-Sophia Children’s Hospital (Rotterdam, the Netherlands). In addition to his research positions, Dr. van den Anker serves as the part-time Chief Medical Officer of ReveraGen BioPharma.

Dr. van den Anker formerly served as Director, Division of Neonatology at Sophia Children’s Hospital and as Director, Division of Pediatric Clinical Pharmacology and Medical Toxicology, at Columbus Children’s Hospital (Columbus, Ohio).

“Dr. van den Anker’s extensive knowledge of pediatric and neonatal clinical pharmacology and expertise in pediatric and neonatal therapies and clinical trials makes him an outstanding resource for assisting our clients in the design and implementation of their pediatric development programs,” said Dr. Peck. “We are delighted that he has joined NDA Partners team of Expert Consultants.”

Dr. van den Anker received his medical degree and Doctorate in Pharmacology from Erasmus University Rotterdam in Rotterdam, the Netherlands. He completed his residency in Pediatrics and a fellowship in Neonatology at Sophia Children’s Hospital in the Netherlands.

About NDA Partners
NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.

Contact
Earle Martin, Chief Executive Officer
Office: 540-738-2550
MartinEarle(at)ndapartners(dot)com

Read the full story at https://www.prweb.com/releases/johannes_n_van_den_anker_md_phd_prominent_neonatal_and_pediatric_clinical_pharmacologist_joins_nda_partners/prweb16304383.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. HyGreen Partners with RCA Medical in Johannesburg, South Africa
2. NeuroCog Trials Appoints Health Care Banker, Josh Spiegel, CFA To Chief Operating Officer
3. Prominent Speakers Offer Lessons for Health and Health Care Quality Innovators
4. SMi Group Reports: 16 Prominent Updates in Pre-Filled Syringes by Big Pharma and Industry Innovators
5. The Access Group Recognized for Oncology Leadership: Agencys Oncology Business Unit Receives Praise from Prominent Industry Publication
6. Mauna Kea Technologies Cellvizio Featured Prominently at 2016 World Congress for Bronchology and Interventional Pulmonology
7. Prominent Physicians Join Juniper Pharmaceuticals Scientific Advisory Board
8. Landmark Trial Entitled "PROMINENT" To Explore The Prevention Of Heart Disease In Diabetic Patients With High Triglycerides And Low HDL-C
9. OncoSec to Present at Prominent Investment Conferences in January
10. Precision for Value Adds Prominent Health Economist Dr. Christopher Blanchette to its Expanding HEOR Team
11. New Study Suggests Prominent Role for Pharmacies In Reducing Asthma-related Illness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2019)... (PRWEB) , ... October 23, 2019 , ... ... were recognized in Baltimore magazine’s November 2019 “Top Docs” issue, representing 22 separate ... , Dr. John Campbell, Orthopedic Surgery: Foot & Ankle, Dr. Rebecca Cerrato, Orthopedic ...
(Date:10/19/2019)... (PRWEB) , ... October 18, 2019 , ... Beginnings Treatment ... to act as the official sponsor of the Alcohol and Other Drug Awareness ... to empower students to make informed decisions around alcohol and other drugs through individual ...
(Date:10/19/2019)... ... October 18, 2019 , ... A new study ... suggests adalimumab use in pregnancy was not associated with an increased risk for ... delivery. The findings were published today in the Public Library of ...
Breaking Medicine Technology:
(Date:10/15/2019)... ... ... Khalieghya Dandie-Evans, a liver transplant recipient from Richmond, Calif. was chosen by ... in the 131st Rose Parade® on New Year’s Day. She will represent the thousands ... the organization’s service area. , Khalieghya, 17, grew up believing it was “normal” to ...
(Date:10/15/2019)... ... 15, 2019 , ... Nashville Fertility Center (NFC) is proud to announce that ... the practice. In addition to treating general infertility, Dr. Van Heertum offers expertise in ... looks forward to Dr. Van Heertum joining the practice and believes she is the ...
(Date:10/10/2019)... ... October 10, 2019 , ... ... information technology (IT) services for the healthcare industry, has completed the first phase ... (PHA) of the Commonwealth of The Bahamas towards a fully integrated health information ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... SoCal Adolescent ... are happy to announce the expansion of our services to better serve the families ... opportunity over this last year to see the extraordinary impact this pre-intervention program has ...
(Date:10/8/2019)... COLLEGE PARK, Md. (PRWEB) , ... October 08, ... ... to observe fungal infection progression in live samples, Meiqing Shi, associate professor with ... in the field. In his latest paper published in Nature Communications, Shi and ...
Breaking Medicine News(10 mins):